[Renoprotecion With Metabolic Syndrome: the Possibility of Receptor Agonist Imidazoline Moxonidine]

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Metabolic syndrome is a growing health concern associated with increased cardiovascular and renal risks.
• Chronic kidney disease (CKD) is a common complication of metabolic syndrome, particularly in obese individuals.
• Sympathetic nervous system overactivity plays a significant role in the pathogenesis of CKD in metabolic syndrome.

Purpose of the Study:

• To review the prevalence, diagnosis, and prognostic significance of renal damage in metabolic syndrome.
• To discuss pathogenetic mechanisms of CKD in obesity and the role of sympathetic nervous system.
• To evaluate antihypertensive drug choices emphasizing metabolic and renal protection, focusing on imidazoline receptor agonists like moxonidine.

Main Methods:

• Literature review of studies on metabolic syndrome, renal damage, and antihypertensive therapies.
• Analysis of pathogenetic mechanisms linking obesity, sympathetic activity, and CKD.
• Evaluation of pharmacological data on imidazoline receptor agonists and their renal protective effects.

Main Results:

• Renal damage is prevalent in metabolic syndrome, impacting prognosis.
• Increased sympathetic nervous system activity contributes to CKD progression in obesity.
• Moxonidine, an imidazoline receptor agonist, demonstrates neuroprotective and renal protective advantages in patients with hypertension, metabolic syndrome, and diabetes.

Conclusions:

• Early diagnosis and management of renal damage in metabolic syndrome are crucial.
• Targeting sympathetic overactivity and utilizing drugs with renal protective properties, such as moxonidine, are key therapeutic strategies.
• Imidazoline receptor agonists offer significant benefits for renal protection in patients with comorbid metabolic and cardiovascular conditions.